このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ICU での ABCDEF バンドルの採用を増やすための行動経済学および人員配置戦略 (BEST-ICU)

2026年10月19日 更新者:University of Nebraska

集中治療室 (BEST ICU) における ABCDEF バンドルの採用を増やすための行動経済と人員配置戦略: 段階的ウェッジクラスターランダム化比較試験

The overarching goal of this study is to support the "real world" assessment of strategies used to foster adoption of several highly efficacious evidence-based practices in healthcare systems that provide care to critically ill adults with known health disparities. Investigators will specifically evaluate two discrete strategies grounded in behavioral economic and implementation science theory (i.e., real-time audit and feedback and registered nurse implementation facilitation) to increase adoption of the ABCDEF bundle in critically ill adults.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Millions of survivors of critical illness worldwide experience profound and frequently persistent physical, mental, and cognitive health impairments that are often preventable through the application of existing knowledge. These impairments are commonly acquired in the intensive care unit (ICU) and are often initiated and/or exacerbated by known racial and socioeconomic health disparities and outdated mechanical ventilation (MV) liberation and symptom management practices. Indeed, ICU-acquired pain, anxiety, delirium, and weakness are associated with numerous adverse health outcomes including prolonged MV, mortality, functional decline, new institutionalization, and severe neurocognitive dysfunction. A robust body of research demonstrates that clinical outcomes improve when integrated, interprofessional approaches to MV liberation and symptom management are applied early in the course of critical illness. One such approach is the ABCDEF bundle. When applied in everyday practice, ABCDEF bundle performance is consistently associated with meaningful improvements in important patient and healthcare system outcomes. Unfortunately, ABCDEF bundle performance remains unacceptably low as clinicians struggle with multiple barriers to bundle delivery.

Investigator's previous work demonstrates bundle-related clinical decision making is indeed complex and frequently influenced by prevailing ICU social norms, common knowledge deficits, and substantial workflow challenges. Missing from the literature are evidence-based implementation strategies that are adaptable, responsive to community needs, and account for the cultural and organizational factors necessary to increase bundle adoption particularly in traditionally under-resourced settings like safety net hospitals. Until this key gap in knowledge is filled, the excessively high morbidity, mortality, costs, and disparities associated with critical care delivery will continue and the public health benefit of the ABCDEF bundle will not be fully realized.

Congruent with NIH policy, the goal of this proposal is to support the "real world" assessment of strategies used to foster adoption of several highly efficacious evidence-based practices in healthcare systems that provide care to critically ill adults with known health disparities. Based on strong preliminary data, the study's overall objective is to evaluate two discrete strategies grounded in behavioral economic and implementation science theory to increase adoption of the ABCDEF bundle in critically ill adults. The strategies being evaluated target a variety of ICU team members and known behavioral determinants of ABCDEF bundle performance.

Investigators will conduct a 3-arm, pragmatic, stepped-wedge, cluster-randomized, trial to evaluate both implementation (primary) and clinical (secondary) effectiveness outcomes. After creating 6 matched pairs of 12 ICUs from 3 discrete safety net hospitals (estimated total N=16,500 patients on MV), they will randomly be assigned within each matched pair to receive either real-time audit and feedback or a Registered Nurse (RN) implementation facilitator and each pair to one of six wedges. At the end of the 27-month trial, implementation and clinical outcomes will collected for an additional 3 months to evaluate the effects of removing the implementation strategies.

Aim 1: Primary Implementation Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on proportional ABCDEF bundle performance (primary study outcome).

Aim 1: Secondary Implementation Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on complete ABCDEF bundle performance.

Aim 2: Primary Clinical Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on duration of invasive mechanical ventilation.

Aim 2: Secondary Clinical Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on other patient-centered outcomes (i.e., new tracheostomy placement; advanced non-invasive respiratory therapy use and duration; ICU, hospital, and 30-day mortality; ICU and hospital length of stay; ICU days with acute brain dysfunction (i.e., ICU delirium and/or coma); ICU physical restraint use; daily and total opioid, benzodiazepine, sedative/hypnotic, antipsychotic, melatonin receptor agonist, and paralytic medication use in ICU stay and at hospital discharge; ICU days with a family visit; discharge disposition; ICU readmission; physical therapy utilization in ICU and at hospital discharge; 30-day hospital readmission; ICU days with significant pain; unplanned extubations; reintubations within 24 hours of extubation; hospital-acquired thromboembolic disease, clinically significant falls acquired during hospitalization, hospital-acquired pressure ulcers).

Aim 3: Identify and describe key stakeholders' experiences with, and perspectives of, real-time audit and feedback and RN implementation.

Aim 3.1: Compare the effects of real-time audit and feedback and RN implementation on work intensity.

Aim 3.2: Compare the acceptability of real-time audit and feedback and RN implementation facilitation.

Aim3.3: Assess the association of work intensity with acceptability and proportional bundle performance.

Aim 3.4: Assess provider perspectives of barriers and facilitators to adoption of real-time audit and feedback and RN implementation.

Building on years of successful collaboration, investigator's experienced interprofessional team is ideally suited to perform the proposed work. Study results are expected to impact the field by developing equitable, efficient, effective, and replicable ways of accelerating the reliable uptake of the highly efficacious evidence-based ICU interventions contained in the ABCDEF bundle. This will dually address known healthcare disparities and ultimately improve the care and outcomes of millions of critically ill adults annually.

研究の種類

介入

入学 (推定)

16500

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Michele C Balas, PhD, RN
  • 電話番号:(614) 949-5555
  • メール:mibalas@unmc.edu

研究連絡先のバックアップ

研究場所

    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • 募集
        • University of Iowa Hospitals and Clinics
        • コンタクト:
        • コンタクト:
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • 募集
        • University of Nebraska Medical Center
        • 主任研究者:
          • Breanna D Hetland, PhD
        • 副調査官:
          • Chris S Wichman, PhD
        • 副調査官:
          • James R Campbell, PhD
        • 副調査官:
          • Ronnie Horner, PHD
        • 副調査官:
          • Jungyoon Kim, PhD
        • コンタクト:
          • Michele C Balas, PhD, RN
          • 電話番号:(402) 559-9758
          • メール:mibalas@unmc.edu
    • Ohio
      • Columbus、Ohio、アメリカ、43201

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age > or = to 19 years at time of ICU admission
  • Received invasive mechanical ventilation while in a cluster ICU
  • Admitted to participating cluster ICU
  • Cluster ICU length of stay of at least 24 hours

Exclusion Criteria:

  • Patient who is admitted to the hospital who is already receiving chronic long-term mechanical ventilation from the home, assisted living, or long-term care setting
  • Prisoners

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Usual care

Usual ICU care

実験的:Audit and Feedback

ICUs receive electronic dashboard that displays realtime ABCDEF bundle performance data

ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data

実験的:RN Implementation Facilitator

ICUs receive a extra RN who helps facilitate ABCDEF bundle implementation

ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportional ABCDEF bundle performance
時間枠:27 months

Defined as the percentage of eligible elements a patient receives on a given ICU day ["bundle dose"].

27 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Complete ABCDEF bundle performance
時間枠:27 months

Defined as a patient day in which every eligible element of the bundle was performed (i.e., 100% of the bundle versus anything less; yes/no).

27 months
Duration of invasive mechanical ventilation
時間枠:27 months

Days spent in ICU on invasive mechanical ventilation

27 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of participants with new tracheotomy placement
時間枠:27 months

Current Procedural Terminology code for tracheotomy during hospitalization

27 months
advanced noninvasive respiratory therapy use and duration
時間枠:27 months

The recorded timestamps for advanced non-invasive respiratory therapy using CPAP, BiLevel Positive Pressure Ventilation (BiPaP), or high flow cannula with oxygen flow rates >20 lpm using a face mask or other airway that is NOT an endotracheal tube will be monitored. Specific data elements in the EHR relevant to advanced non-invasive respiratory therapy will be examined. This may include.

  • Clinical orders for the initiation of BiPaP
  • Respiratory therapy logs of pressure setting management
  • Ventilator settings and parameters recorded over time.

Once the data is organized, the duration of advanced non-invasive respiratory therapy for each patient will be calculated using the following formula:

Duration (in hours) = CPAP/BiPaP/High Flow Oxygen Initiation Time - CPAP/BiPaP/High Flow OxygenTermination Time

27 months
Number of participants with an ICU mortality
時間枠:27 months

A death event that is recorded in the electronic health record (EHR) that occurred after index ICU admission and prior to the index ICU discharge date and time

27 months
Number of participants with a hospital mortality
時間枠:27 months

A death event that is recorded in the EHR that occurred after index ICU admission and prior to discharge from the hospital on the index hospital stay.

27 months
Number of participants who die within 30 days of hospital discharge
時間枠:27 months

A death event that is recorded in the EHR that occurs within 30 days of the date of hospital discharge from the index hospital stay.

27 months
ICU length of stay (LOS)
時間枠:27 months

Date and time of ICU discharge minus the date and time of ICU admission. Each ICU stay will be recorded as unique ICU stays as a unique ICU encounter.

27 months
hospital LOS
時間枠:27 months

Date and time of hospital discharge minus the date and time of first encounter during the hospital encounter

27 months
ICU days with acute brain dysfunction
時間枠:27 months

Will record ICU days with delirium. A delirious day would include a 24-hour period with at least one Confusion Assessment Method ICU (CAM ICU) score that is measured as positive. The total would include the total number of days for which CAM ICU is measured to be positive. ICU coma days: Will record any day for which patients exhibit level of arousal scores consistent with coma (Richmond agitation/sedation score -4 or -5, Sedation agitation score of 1 or 2) and add the total number of coma days throughout any given ICU stay, and across all ICU stays within a hospitalization.

27 months
ICU days with physical restraint use
時間枠:27 months

Physical restraint status codes will be identified using the International Classification of Disease code Z78.1 "physical restraint status".

27 months
Opioid, benzodiazepine, sedative/hypnotic, and antipsychotic medication use in ICU and at hospital discharge
時間枠:27 months

Opioid, benzodiazepine, sedative/hypnotic, antipsychotic medication, and melatonin receptor agonist medication use in ICU and at hospital discharge as recorded in EHR

27 months
Discharge destination
時間枠:27 months

Will review hospital discharge destination coded as home, home with home health, short term skilled nursing facility, long term nursing facility, acute rehabilitation hospital, long-term acute care hospital, hospice, acute care hospital, death.

27 months
Number of participants with an ICU readmission
時間枠:27 months

Will be coded yes if a patient has at least one readmission to any ICU following discharge from the index ICU stay.

27 months
Number of participants with 30 day hospital readmission
時間枠:27 months

Coded yes if a patient has at least one hospital readmission following discharge from the index hospital stay. Importantly, will only be able to track same-hospital readmissions.

27 months
Number of participants with physical therapy use in ICU and post discharge
時間枠:27 months

Will collect data regarding daily interactions with physical therapy.

27 months
Days with significant pain
時間枠:27 months

Will define an ICU Day as having an episode of significant pain if any of the below are documented; Numeric rating score: A score of > 7 will be considered significant pain; critical care pain observation tool: A score > 2 will be considered significant pain; Behavioral pain scale: A score > 5 will be considered significant pain; Defense and Veterans Pain Rating Scale: A score > 4 will be considered significant pain; Pain in Alzheimer Disease score: A score > 4 will be considered significant pain

27 months
Number of participants with a reintubation within 24 hours of extubation
時間枠:27 months

Will assess for evidence of an order for intubation that occurs < 24 hours following evidence of extubation, or a prior order for extubation.

27 months
Number of participants with an unplanned extubation
時間枠:27 months

Will assess for evidence of extubations that do not follow provider orders for an extubation and/or are charted as unordered.

27 months
Number of participants with hospital acquired thromboembolic disease
時間枠:27 months

Will query for International Classification of Disease codes associated with thromboembolic disease. Diagnosis codes must be a secondary diagnosis code / hospital acquired

27 months
Number of participants with a hospital acquired fall with injury
時間枠:27 months

Will record fall and trauma coding consistent with the Center for Medicare Services Health Acquired Conditions specification for fracture, dislocation, and intracranial injury.

27 months
Number of participants with a hospital acquired pressure ulcer
時間枠:27 months

The codes for hospital acquired pressure ulcer will be consistent with the Center for Medicare Services Hospital Acquired Conditions coding.

27 months
ICU days with family visit
時間枠:27 months

Electronic health record documentation of family visit that occurred during ICU stay

27 months
work intensity
時間枠:27 months

6 item National Aeronautics and Space Administration Task Load Index; Higher scores indicate higher work intensity

27 months
acceptability
時間枠:27 months

4 item Acceptability of Intervention Measure; higher scores indicate greater acceptability

27 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Michele C Balas, PhD, RN、University of Nebraska

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年7月1日

一次修了 (推定)

2028年4月1日

研究の完了 (推定)

2028年4月1日

試験登録日

最初に提出

2023年12月5日

QC基準を満たした最初の提出物

2023年12月13日

最初の投稿 (実際)

2023年12月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月23日

QC基準を満たした最後の更新が送信されました

2026年10月19日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 0794-23-FB
  • 1UG3HL165740-01A1 (米国 NIH グラント/契約)
  • 4UH3HL165740-02 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

To support study replication and extension, all scientific data including operations and clinical data necessary for replication of this project will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first) in an appropriate online repository. Data used for analysis will be stored in comma-separated values file format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked as well. Original data will be maintained at the principal investigator's institution . There will be no restriction to sharing the data.

IPD 共有時間枠

To support study replication and extension, all scientific data including operations and clinical data necessary for replication of this project will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first) in an appropriate online repository. Data used for analysis will be stored in comma separated values format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked. Original data will be maintained at the principal investigator's institution . There will be no restriction to sharing the data.

IPD 共有アクセス基準

To support study replication and extension, all scientific data, including operational and clinical data necessary for replicating this project, will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first), in an appropriate online repository. Data used for analysis will be stored in comma-separated values format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked. Original data will be maintained at the principal investigator's institution. There will be no restriction to sharing the data.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。